Skip to content
10-K

Annual Report

Monopar Therapeutics MNPR

0001437749-26-010025

← back to feed
Filed
Mar 27, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Stock Repurchased FY 2025 · Dec 31, 2025 $35M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$12.2M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$6.4M
Cash And Equivalents FY 2025 · Dec 31, 2025 $61.83M
Cash And Equivalents FY 2025 · Dec 31, 2024 $45.82M
Stockholders Equity FY 2025 · Dec 31, 2025 $137.83M
Stockholders Equity FY 2025 · Dec 31, 2024 $55.04M
Stockholders Equity FY 2025 · Dec 31, 2023 $5.59M
Current Liabilities FY 2025 · Dec 31, 2025 $2.74M
Current Liabilities FY 2025 · Dec 31, 2024 $5.25M
Total Liabilities FY 2025 · Dec 31, 2025 $2.89M
Total Liabilities FY 2025 · Dec 31, 2024 $5.25M
Current Assets FY 2025 · Dec 31, 2025 $140.46M
Current Assets FY 2025 · Dec 31, 2024 $60.29M
Total Assets FY 2025 · Dec 31, 2025 $140.72M
Total Assets FY 2025 · Dec 31, 2024 $60.29M
Eps Basic FY 2025 · Dec 31, 2025 −$1.85
Eps Basic FY 2025 · Dec 31, 2024 −$4.11
Sga Expense FY 2025 · Dec 31, 2025 $6.8M
Sga Expense FY 2025 · Dec 31, 2024 $3.16M
Rd Expense FY 2025 · Dec 31, 2025 $9.9M
Rd Expense FY 2025 · Dec 31, 2024 $13.01M
Net Income FY 2025 · Dec 31, 2025 −$13.72M
Net Income FY 2025 · Dec 31, 2024 −$15.59M
Operating Income FY 2025 · Dec 31, 2025 −$16.7M
Operating Income FY 2025 · Dec 31, 2024 −$16.16M
Revenue FY 2025 · Dec 31, 2025 $0